Article

Key Stakeholders Needed in the Development of Outpatient Naloxone Policies

Conference|PAINWeek Conference

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses key stakeholders involved in developing and implementing outpatient naloxone policies.

Juliana Zschoche, PharmD, emergency medicine clinical pharmacy specialist at Johns Hopkins Hospital, discusses key stakeholders involved in developing and implementing outpatient naloxone policies.

Related Videos
Genetic engineering and gene manipulation concept. Hand is replacing part of a DNA molecule - Image credit: vchalup | stock.adobe.com
Related Content
Miniature people and the concept of an aging society - Image credit: Hyejin Kang | stock.adobe.com
April 9th 2025

How Old Is Old? Rethinking the “Normal” Process of Aging

Troy Trygstad, PharmD, PhD, MBA, Pharmacy Times Editor in Chief
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Stethoscope and paper with Huntington's Disease written -- Image credit: syahrir | stock.adobe.com
April 9th 2025

AAN 2025: Pridopidine Shows Sustained Benefits on Progression, Cognition, and Motor Function in Patients With HD

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
HOPA 2025: Matthew Lei, PharmD, BCOP, Shares Critical Themes and Hot Topic Sessions
April 9th 2025

HOPA 2025: Matthew Lei, PharmD, BCOP, Shares Critical Themes and Hot Topic Sessions

Matthew M. Lei, PharmD, BCOP Alana Hippensteele, Lead Editor
Child with a migraine -- Image credit: irena_geo | stock.adobe.com
April 8th 2025

AAN 2025: Fremanezumab Superior to Placebo in Reducing Monthly Migraine Days in Children and Adolescents

Gillian McGovern, Associate Editor